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A multicentre, randomised controlled, non-inferiority trial, comparing
nasal high flow with nasal continuous positive airway pressure as primary
support for newborn infants with early respiratory distress born in
Australian non-tertiary special care nurseries (the HUNTER trial): study
protocol
Abstract
Introduction Nasal high-flow (nHF) therapy is a popular mode of respiratory support for newborn infants.
Evidence for nHF use is predominantly from neonatal intensive care units (NICUs). There are no randomised
trials of nHF use in non-tertiary special care nurseries (SCNs). We hypothesise that nHF is non-inferior to
nasal continuous positive airway pressure (CPAP) as primary support for newborn infants with respiratory
distress, in the population cared for in non-tertiary SCNs.
Methods and analysis The HUNTER trial is an unblinded Australian multicentre, randomised, non-
inferiority trial. Infants are eligible if born at a gestational age ¿31 weeks with birth weight ¿1200 g and
admitted to a participating non-tertiary SCN, are 1 hour. Infants are randomised to treatment with either nHF
or CPAP. The primary outcome is treatment failure within 72 hours of randomisation, as determined by
objective oxygenation, apnoea or blood gas criteria or by a clinical decision that urgent intubation and
mechanical ventilation, or transfer to a tertiary NICU, is required. Secondary outcomes include incidence of
pneumothorax requiring drainage, duration of respiratory support, supplemental oxygen and hospitalisation,
costs associated with hospital care, cost-effectiveness, parental stress and satisfaction and nursing workload.
Ethics and dissemination Multisite ethical approval for the study has been granted by The Royal Children's
Hospital, Melbourne, Australia (Trial Reference No. 34222), and by each participating site. The trial is
currently recruiting in eight centres in Victoria and New South Wales, Australia, with one previous site no
longer recruiting. The trial results will be published in a peer-reviewed journal and will be presented at
national and international conferences.
Trial registration number Australian and New Zealand Clinical Trials Registry (ANZCTR):
ACTRN12614001203640; pre-results.
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ABSTRACT
Introduction Nasal high-flow (nHF) therapy is a popular 
mode of respiratory support for newborn infants. Evidence 
for nHF use is predominantly from neonatal intensive care 
units (NICUs). There are no randomised trials of nHF use in 
non-tertiary special care nurseries (SCNs). We hypothesise 
that nHF is non-inferior to nasal continuous positive airway 
pressure (CPAP) as primary support for newborn infants 
with respiratory distress, in the population cared for in 
non-tertiary SCNs.
Methods and analysis The HUNTER trial is an unblinded 
Australian multicentre, randomised, non-inferiority trial. 
Infants are eligible if born at a gestational age ≥31 weeks 
with birth weight ≥1200 g and admitted to a participating 
non-tertiary SCN, are <24 hours old at randomisation and 
require non-invasive respiratory support or supplemental 
oxygen for >1 hour. Infants are randomised to treatment 
with either nHF or CPAP. The primary outcome is treatment 
failure within 72 hours of randomisation, as determined by 
objective oxygenation, apnoea or blood gas criteria or by 
a clinical decision that urgent intubation and mechanical 
ventilation, or transfer to a tertiary NICU, is required. 
Secondary outcomes include incidence of pneumothorax 
requiring drainage, duration of respiratory support, 
supplemental oxygen and hospitalisation, costs associated 
with hospital care, cost-effectiveness, parental stress and 
satisfaction and nursing workload.
Ethics and dissemination Multisite ethical approval 
for the study has been granted by The Royal Children’s 
Hospital, Melbourne, Australia (Trial Reference No. 34222), 
and by each participating site. The trial is currently 
recruiting in eight centres in Victoria and New South Wales, 
Australia, with one previous site no longer recruiting. The 
trial results will be published in a peer-reviewed journal and 
will be presented at national and international conferences.
Trial registration number Australian and New Zealand 




Preterm birth, at <37 weeks’ gestational 
age (GA), affecting about 15 million infants 
annually, is a major cause of morbidity and 
mortality worldwide. About one million 
infants die from complications of prematu-
rity every year.1 In Australia, about 9% of all 
births are preterm.2 A major contributor to 
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 ► This is the first study to compare nasal high-flow 
with nasal continuous positive airway pressure as 
respiratory support for newborn infants in non-
tertiary settings.
 ► The study is well-powered to detect non-inferiority 
of nasal high-flow with a non-inferiority margin of 
10%; the use of a non-inferiority study design is 
appropriate given the advantages of nasal high-flow 
over nasal continuous positive airway pressure.
 ► The study includes assessment of parental stress, 
nursing workload and financial costs.
 ► Blinding of the allocated respiratory support modes 
is not possible, so objective criteria were specified 
for the primary outcome of treatment failure.
 ► Some infants in the nasal high-flow group will have 
received a brief period of nasal continuous positive 
airway pressure prior to randomisation.
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mortality and morbidity in preterm infants is respiratory 
distress syndrome (RDS) due to surfactant deficiency in 
the lungs, which leads to many preterm infants requiring 
respiratory support soon after birth; the proportion 
of infants who develop RDS increases with lower GA. 
However, about 80% of preterm infants are born 
moderate to late preterm (32–36 weeks’ GA),2 where 
RDS is less common. Respiratory symptoms in this more 
mature preterm population, and in term infants, may be 
due to conditions such as transient tachypnoea of the 
newborn or infection.
It is estimated that 2.5%–5% of all newborn infants have 
respiratory distress.3 In Australia, most of these infants are 
born in a non-tertiary hospital and cared for in a special 
care nursery (SCN), where (depending on the level of 
neonatal care available) they may be treated with supple-
mental oxygen and/or ‘non-invasive’ respiratory support 
from nasal continuous positive airway pressure (CPAP). 
However, if these treatments are not available such as in 
some smaller SCNs, or not successful, or if an infant is 
born very preterm (<32 weeks’ gestation) or very small 
(<1250 g), then the infant usually needs to be transferred 
to a tertiary-level neonatal intensive care unit (NICU). In 
Australia, neonatal intensive care is centralised in large 
metropolitan centres, and maternal and infant transfers 
from regional or rural centres involve large distances and 
significant costs.
the standard non-invasive respiratory support: cPAP
CPAP uses large prongs in the nose, or a mask over the 
nose, fitted firmly to the infant’s face. The prongs or mask 
deliver heated and humidified air and oxygen under 
pressure. CPAP can be used effectively as the primary 
mode of respiratory support (the first mode of respira-
tory support applied after admission to the neonatal unit 
soon after birth) in infants with respiratory distress, even 
those born at 25–30 weeks’ gestation.4 5 When used in 
Australian non-tertiary SCNs to treat late preterm and 
term infants with respiratory distress, CPAP reduces the 
need for transfer to a tertiary NICU, and it reduces costs 
in comparison to the use of supplemental oxygen alone.6 
However, CPAP has been associated with an increased risk 
of pneumothorax compared with supplemental oxygen 
alone.6 7
CPAP is a widely used method of respiratory support 
in larger Australian SCNs,8 9 but it has some disadvan-
tages. CPAP fixation devices are bulky and cover much 
of the infant’s face, interfering with parental interac-
tion and feeding; trauma to the nasal skin or septum is 
a commonly reported complication.10 Nursing vigilance 
is required to ensure that an adequate seal (and hence 
pressure) is maintained without causing nasal injury. For 
these reasons, and others including limits on staff and 
equipment, CPAP is not currently a feasible therapy in 
smaller Australian SCNs (with birth rates mostly <1500/
year) that infrequently care for infants who require respi-
ratory support.
the new therapy: nasal high-flow
In recent years, nasal high-flow (nHF) therapy, a newer 
form of non-invasive respiratory support, has become 
popular as an alternative to CPAP around the world, 
including in Australasian SCNs.9 11–15 nHF therapy delivers 
heated, humidified, blended oxygen and air via small 
binasal prongs, using gas flows of at least 1 L/min.16 While 
nHF therapy has been adopted by many NICUs around 
the world, there has until recently been relatively little 
evidence to support this practice. The increasing popu-
larity of nHF seems to be due to its reported advantages 
over CPAP: it is easier to apply and maintain, more 
comfortable for infants, associated with less nasal trauma 
and preferred by parents and nursing staff.17–20 If nHF 
was demonstrated to be an effective mode of respiratory 
support in non-tertiary SCNs, these factors would make it 
the preferred interface in this setting.
clinical trials of nHF in newborn infants
Preventing extubation failure in NICUs
The majority of published randomised controlled trials 
(RCTs) of nHF have evaluated its use as an alterna-
tive to CPAP, as postextubation respiratory support. An 
updated Cochrane Review20 of these trials, published in 
2016, found no difference in rates of treatment failure or 
reintubation in infants treated with postextubation nHF, 
compared with those treated with CPAP. The nHF infants 
were noted to have lower rates of nasal trauma and a small 
reduction in the risk of pneumothorax.
Primary respiratory support for newborn infants
Prior to the HUNTER trial commencing, there was little 
evidence from RCTs to support the use of nHF as primary 
support for newborn infants. Yoder et al21 conducted 
an RCT in 432 infants, of whom about one-third were 
included in an ‘early support’ arm. There was no differ-
ence between the nHF and CPAP groups in need for 
intubation or in other neonatal morbidities. Studies by 
Iranpour et al22 and Kugelman et al,23 each including 
approximately 70 infants, compared nHF with CPAP and 
nasal intermittent positive airway pressure, respectively, as 
early respiratory support for preterm infants; they found 
no difference between groups in rates of treatment failure 
or other important outcomes.
Within the past year, two larger RCTs evaluating nHF 
as primary respiratory support in NICUs have been 
published. The HIPSTER trial24 included 564 preterm 
infants of mean 32 weeks’ GA and 1.7 kg in birth weight, 
not previously treated with surfactant, in nine NICUs in 
Australia and Norway; nHF use resulted in a higher rate 
of treatment failure (based on objective clinical criteria) 
than CPAP (25.5% vs 13.3%, p<0.01), but no greater 
risk of intubation, likely due to the use of ‘rescue’ CPAP 
in infants with nHF failure. Lavizzari et al25 studied 316 
infants of mean 33 weeks’ GA and 1.9 kg in birth weight 
in an Italian NICU. They found no difference in rates of 
treatment failure (mechanical ventilation within 72 hours) 
between infants treated with nHF and those treated with 
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Figure 1 Schedule of enrolment, interventions and 
assessments: the HUNTER trial. HF, high flow; CPAP, 
continuous positive airway pressure.
CPAP and/or biphasic positive airway pressure (10.8% vs 
9.5%, p=0.71). However, it is notable that infants in this 
study could be intubated, treated with surfactant and 
extubated (‘INSURE’ treatment), without being classed 
as having treatment failure. Surfactant use was common, 
occurring in >40% of infants in both treatment groups.
While providing important guidance on the use of 
primary nHF in NICUs, it is important to recognise that 
the results of these studies cannot be directly applied 
to use in non-tertiary SCNs, where there is currently no 
high-quality evidence to guide practice. Staffing in SCNs 
is different to that in tertiary NICUs, and infants in SCNs 
have different antenatal exposures, GAs and pathologies.
Summary and rationale
The reported advantages of nHF—easier nursing care, 
improved feeding and parental interaction, reduced nasal 
trauma and greater infant comfort—have led to wide-
spread adoption of this new therapy. While there are now 
a number of studies assessing nHF use in the NICU, there 
are no published trials that study the efficacy and safety 
of nHF compared with CPAP as early respiratory support 
for newborn infants in SCNs. The reference treatment 
against which non-inferiority is being assessed, CPAP, 
has been shown to be effective in SCNs in a study with 
similar inclusion criteria and CPAP treatment protocols.6 
If proven to be effective and safe, the ease of use of nHF 
would mean that it could be widely applied to infants with 
respiratory distress in non-tertiary SCNs, both in Australia 
and around the world, potentially reducing the need for 
transfer to a tertiary NICU—reducing costs and keeping 
mothers and their babies together. Conversely, if nHF 
is shown to be unsafe or significantly less effective than 
CPAP, this will guide clinicians to avoid nHF treatment 
of newborn infants outside NICUs. The above consider-
ations led to the adoption of a non-inferiority trial design.
MetHodS And AnAlySIS
Study design
HUNTER is a multicentre, randomised, non-inferiority 
trial, including newborn infants cared for in Australian 
non-tertiary SCNs, who require early non-invasive respi-
ratory support in the first 24 hours of life. A schedule of 
enrolment, interventions and assessments is shown in the 
figure.
Aim
The aim of the HUNTER trial is to determine whether 
nHF is non-inferior to CPAP in avoiding treatment failure 
when used as early non-invasive respiratory support for 
newborn infants cared for in Australian non-tertiary 
SCNs.
Blinding
Blinding of the allocated treatment is not feasible, as the 
mode of respiratory support is clearly apparent to medical 
and nursing staff and parents/guardians. We have there-
fore defined objective criteria for the primary outcome 
to minimise potential bias, and have provided guidance 
to clinicians considering the need to escalate respiratory 
support and/or arrange transfer to a tertiary NICU.
outcomes
The primary outcome will be assessed on a hypothesis 
of non-inferiority. Outcomes, eligibility criteria and the 
CPAP treatment protocol are similar to those of a study in 
Australian SCNs that demonstrated the efficacy of CPAP 
in comparison to passive oxygen for preventing treatment 
failure.6 The major change from that study is a reduction 
in the fraction of inspired oxygen (FiO2) threshold for 
treatment failure from 0.50 to 0.40, in line with current 
international practice to reduce neonatal oxygen expo-
sure.
Primary outcome
The primary outcome is treatment failure within 72 hours 
of randomisation. Treatment failure occurs when an 
infant has reached maximal therapy for their allocated 
treatment (nHF 8 L/min or CPAP 8 cm H2O) and one or 
more of the following criteria are satisfied:
1. Sustained increase in oxygen requirement: fraction of 
inspired oxygen (FiO2) ≥0.40 for more than 1 hour to 
maintain peripheral oxygen saturation (SpO2) 91%–
95%.
2. Respiratory acidosis: both pH <7.20 and pCO2 >60 
millimetres of mercury (mm Hg) on two blood gas 
samples (which can be capillary, venous or arterial), 
with the first sample collected at least 1 hour after 
initiation of the assigned treatment and the second 
sample taken at least 1 hour after the first.
3. Frequent or severe apnoea: more than one apnoea 
receiving positive pressure ventilation within any 
24 hours period, or six or more apnoeas in any 
6-hour period receiving intervention (stimulation or 
increased oxygen).
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4. The treating paediatrician determines that urgent 
intubation and mechanical ventilation is required.
5. The treating paediatrician determines that the 
infant requires transfer to a tertiary NICU, through 
consultation with the local neonatal transport service.
Secondary outcomes
The secondary outcomes are as follows:
1. Cost: estimated differences between the interventions 
based on the costs of equipment, care in SCNs and 
NICUs, costs associated with hospital stay, costs to 
the family and the costs of transfer (both infant and 
maternal).
2. Mortality (specified as a significant adverse event).
3. Pneumothorax requiring drainage via needle 
thoracocentesis or intercostal catheter insertion 
(specified as a significant adverse event).
4. Duration of supplemental oxygen (hours).
5. Oxygen supplementation at 28 days of age, or at 
36 weeks’ corrected GA for infants born <32 weeks’ 
gestation.
6. Mechanical ventilation via an endotracheal tube in 
the first 72 hours after randomisation and at any time 
prior to discharge home.
7. Duration of respiratory support (hours): including 
hours of nHF, CPAP and mechanical ventilation.
8. Duration of hospital admission and duration of 
admission to a tertiary NICU (days).
9. Incidence of nasal trauma.
10. Weight gain and feeding performance, including 
weight gain from birth to hospital discharge, 
proportion of infants fully breastfed at discharge, 
number of days receiving any intravenous fluids and 
number of days to reach full suck feeds (defined as 
tolerating suck feeds without any requirement for 
intravenous fluids or nasogastric/orogastric feeds 
for >24 hours).
11. Parental stress and satisfaction, measured using a 
modified version of the validated Parental Stressor 
Scale: NICU,26 assessed as soon as possible after 
treatment has ceased, or prior to transfer to a NICU.
12. Nursing workload and treatment preference, 
measured using the Professional Assessment of 
Optimal Nursing Care Intensity Scale tool,27 and by 
questionnaire.
Setting
The trial has been enrolling infants in nine non-tertiary 
SCNs in Victoria and New South Wales, Australia. All 
participating SCNs routinely care for newborn infants 
with respiratory distress, using CPAP as the standard 
non-invasive support mode; participating centres did not 
previously use nHF to treat newborn infants. No Austra-
lian SCNs provide ongoing mechanical ventilation; this 
is only provided while awaiting transfer of the infant 
to a tertiary NICU. All participating centres administer 
exogenous surfactant if the infant requires intubation for 
RDS prior to retrieval by the neonatal transport team; the 
standard of care is that all these infants are transferred 
to a tertiary NICU. Two participating centres have some 
experience using the ‘INSURE’ (Intubate, Surfactant, 
Extubate) procedure28 in select infants with the support 
of the neonatal transport service (after which NICU 
transfer could potentially be avoided), but this is an infre-
quent practice that is staff dependent. The participating 
SCNs have 24 hour on-site junior paediatric staff and a 
designated on-call consultant paediatrician available to 
advise management and/or attend as required. Some 
participating centres have one or two consultant staff with 
specialist neonatal training, but most Australian SCNs do 
not.
eligibility criteria
Infants are eligible for inclusion in the trial if:
1. They are born at ≥31 weeks’ GA by best obstetric 
estimate and have birth weight ≥1200 g; and
2. They are admitted to the SCN of a participating centre 
and are <24 hours old at the time of randomisation; 
and
3. They require non-invasive respiratory support 
after admission to the SCN (at clinician discretion) 
or require any supplemental oxygen to maintain 
SpO2 91%–95% for more than 1 hour.
Infants are excluded from the trial if:
1. They have received more than 2 hours of CPAP prior to 
randomisation; or
2. They have previously been intubated (including 
intubation for suctioning below the cords in the 
delivery room), or immediately need intubation, as 
determined by the attending paediatrician; or
3. They have a known major congenital abnormality 
that may impact on the infant’s condition after birth 
(eg, complex congenital cardiac disease, upper 
airway obstruction, gastrointestinal malformation); 
or
4. They are judged by their paediatrician to require 
transfer to another hospital for ongoing care (the 
reason for this decision will be clearly documented).
randomisation
Randomisation will be prestratified by centre and 
according to GA at birth: <34 weeks’ GA and ≥34 weeks’ 
GA. Within each stratum, a 1:1 allocation ratio and block 
randomisation with variable block sizes (4, 6 or 8) will be 
used. Multiple births with more than one eligible infant 
will be randomised individually. Each participating centre 
will be provided with consecutively numbered, sealed 
opaque randomisation envelopes containing the assigned 
treatment allocation. The appropriate envelope will be 
opened after written consent has been obtained and 
the infant has become eligible for the trial; the assigned 
treatment will then immediately be applied to the infant. 
Random sequences were generated in SAS v9.4 by author 
Arnolda.
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clinical management
Eligible and consented infants will be randomised to 
treatment with either nHF or CPAP; allocated treatment 
will be applied immediately after randomisation. Infants 
in both groups will receive standard supportive care as 
per local policies, for example, blood tests, antibiotics, 
intravenous fluids/nutrition and enteral feeds. In both 
groups, supplemental oxygen will be adjusted to main-
tain SpO2 91%–95%. Chest X-rays and blood gas analyses 
are not mandated prior to randomisation, and the timing 
of these investigations will be a physician discretion in 
keeping with the pragmatic trial design; however, it is 
expected that most enrolled infants will have these inves-
tigations performed as per local guidelines.
Interventions
nHF therapy is defined as heated, humidified gas 
(blended air/oxygen) delivered at gas flows of 5–8 L/
min via the Fisher & Paykel ‘Optiflow Junior’ circuit and 
prongs (Fisher & Paykel Healthcare, Auckland, New 
Zealand).
CPAP is defined as the use of short binasal prongs or 
nasal mask to deliver heated, humidified gas (blended 
air/oxygen) using a ‘bubble’ CPAP device (any brand 
may be used) with set pressures of 5–8 cm H2O.
Intervention group: nHF
1. A nasal cannula size should be selected that maintains 
a leak at the nares.
2. The starting flow will be 6 L/min for all infants.
3. Increasing nHF support: Gas flow may be increased to 
a maximum of 8 L/min.
4. If treatment failure criteria are satisfied, infants 
should receive CPAP 8 cm H2O and then be managed 
as per the CPAP group protocol:
a. If treatment failure criteria are again satisfied 
when the infant is receiving CPAP 8 cm H2O, it 
is recommended that the treating paediatrician 
consider referral to the local neonatal transport 
service for advice and/or transfer of the infant to a 
tertiary NICU, and surfactant may be administered 
at the paediatrician’s discretion according to the 
unit’s individual policy.
b. If the infant’s condition is improving, the CPAP 
pressure should be weaned, and nHF may be 
reinstituted at the paediatrician’s discretion.
5. Decreasing and ceasing nHF support.
a. Gas flow may be decreased (in decrements of 1 L/
min) or ceased if there is no supplemental oxygen 
requirement (infant is receiving air), or if the 
infant has required FiO2 <0.25 for >24 hours.
b. nHF should be ceased when the gas flow is 5 L/
min, and there is no supplemental oxygen 
requirement, or the infant has required FiO2 <0.25 
for >24 hours:
c. If nHF is ceased, infants may receive ongoing 
oxygen supplementation via ‘low-flow’ nasal 
cannulae, cot oxygen or head-box oxygen.
d. After ceasing nHF, if non-invasive breathing 
support is again required, nHF should be 
recommenced at ≥5 L/min and managed as above.
6. Infants randomised to nHF will not receive CPAP after 
randomisation, unless treatment failure criteria are 
met.
Standard care group: CPAP
1. The starting set pressure will be 6 cm H2O for all 
infants.
2. Increasing CPAP support: the set CPAP pressure may 
be increased to a maximum of 8 cm H2O.
3. If treatment failure criteria are satisfied, it is 
recommended that the treating paediatrician 
consider referral to the local neonatal transport 
service for advice and/or transfer of the infant to a 
tertiary NICU, and surfactant may be administered at 
the paediatrician’s discretion according to the unit’s 
individual policy.
4. Decreasing and ceasing CPAP support:
a. The set pressure may be decreased (in decrements 
of 1 cm H2O) or ceased if there is no supplemental 
oxygen requirement (infant is receiving air), or if 
the infant has required FiO2 <0.25 for >24 hours.
b. CPAP should be ceased when the set pressure is 
5 cm H2O, and there is no supplemental oxygen 
requirement, or the infant has required FiO2 <0.25 
for >24 hours.
c. If CPAP is ceased, infants may receive ongoing 
oxygen supplementation via ‘low-flow’ nasal 
cannulae, cot oxygen or head-box oxygen.
d. After ceasing CPAP, if non-invasive breathing 
support is again required, CPAP should be 
recommenced at ≥5 cm H2O and managed as 
above.
5. Infants randomised to CPAP will not receive nHF at 
any stage of their admission.
Sample size calculation
Non-inferiority of nHF will be determined using the abso-
lute risk difference (RD) and 95% CI for the primary 
outcome of treatment failure within 72 hours of randomi-
sation. We have set the margin of non-inferiority at 10%. 
Thus, for nHF to be non-inferior to CPAP, the upper 
limit of the two-sided 95% CI of the RD must be <10%. 
This margin was adopted after agreement between the 
site investigators and our parent representative; it is 
equivalent to the smallest margin chosen in previously 
published non-inferiority trials of neonatal respiratory 
support,25 29 and it is narrower than in most non-inferi-
ority trials published in the adult medical literature.
Based on pretrial data from six non-tertiary SCNs, we 
estimate the rate of the primary outcome in the CPAP 
group will be 17%. A sample size of 750 infants (375 
infants in each group) is required to demonstrate non-in-
feriority of nHF with 90% power: that is, to be 90% sure 
that the upper limit of a two-sided 95% CI will exclude a 
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difference in favour of CPAP of more than 10% (www. 
sealedenvelope. com/ power/ binary- noninferior).
Statistical analysis and economic evaluation plan
Statistical analysis will be performed by authors Manley 
and Arnolda  with assistance from the Trial Steering 
Committee. Data will be exported from an electronic data-
base to an electronic statistical package for analysis. The 
primary analysis will be by intention to treat. A secondary 
per protocol analysis will also be performed for the primary 
outcome and any important differences reported, as is 
recommended for non-inferiority trials.30
The difference between the groups in the incidence of the 
primary outcome will be reported using RD with two-sided 
95% CI. Subgroup analysis by GA at birth will be performed 
for the primary outcome and selected secondary outcomes. 
Dichotomous secondary outcomes will be compared 
with an RD (two-sided 95% CI) and a Χ2 test. Continuous 
secondary outcomes will be compared by the appropriate 
parametric (t-test) or non-parametric (Mann-Whitney U) 
test. The primary outcome will be assessed on a hypothesis 
of non-inferiority; all secondary outcomes will be assessed 
against a hypothesis of superiority.
Cost-effectiveness analysis will be conducted from the 
healthcare system perspective, incorporating the costs of 
inpatient stay including the associated device and patient 
transfer costs. Routinely available costs of inpatient stay 
will be sourced from the hospital costing units. To inform 
whether it is cost-effective to incorporate nHF or CPAP 
into the existing health system, decision analysis will be 
constructed based on the primary outcome and associ-
ated hospital costs. Univariate and probabilistic sensitivity 
analyses will be conducted to test the impact of uncer-
tainty in data.
Nursing workload measures will be analysed using 
longitudinal methods, as these are provided by the 
nurse primarily responsible for the infant at the hospital 




Multisite ethical approval for the study has been granted by 
The Royal Children’s Hospital, Melbourne, Australia (No. 
34222, current approved protocol version 6, 15 May 2017). 
Site-specific governance approval has been granted by 
the following human research ethics committees: Victoria, 
Australia: Western Health, Northern Health, Eastern 
Health, Barwon Health and Monash Health; New South 
Wales, Australia: Central Coast Local Health District and 
Illawarra Shoalhaven Local Health District.
recruitment and consent
In all cases, prospective, written consent will be obtained 
from a parent or guardian. Consent may be either ante-
natal or postnatal.
For postnatal consent, eligible infants will be identified 
after birth and their parents or guardians approached 
as soon as possible for prospective consent. Parents or 
guardians of infants who are not yet eligible but are likely 
to become eligible (eg, infants requiring supplemental 
oxygen who are likely to continue on this treatment) may 
also be approached. In some cases, antenatal consent 
may be obtained (eg, when a preterm birth is planned). 
Written consent will be recorded on the trial patient 
information and consent form.
Consent will be obtained by a doctor or nurse who has 
been trained in obtaining consent for the trial and who has 
received education regarding the trial protocol. Wherever 
possible, consent will be obtained by someone not directly 
involved in the clinical care of the infant at the time.
data collection, storage and access
Data will be sourced from the infant’s bedside observa-
tion chart, medical and nursing notes, pathology results, 
electronic monitors, the mother’s medical chart and 
verbally and by questionnaire from parents/guardians 
and nursing staff. Data will be de-identified and entered 
onto a paper case record form and subsequently will be 
entered into a secure, web-based electronic database. 
Only the members of the Trial Steering Committee will 
have access to the final dataset.
Monitoring and safety
An independent data safety and monitoring committee 
(DSMC) has been convened, consisting of two neona-
tologists, a paediatric emergency specialist and a 
statistician. An early safety review was undertaken after 
150 infants were recruited to the trial, and further safety 
reviews are planned approximately 6 monthly. A single 
review of the primary outcome and its components was 
planned, after the primary outcome was known for 375 
participants.
Defined serious adverse events (SAEs) for the study are:
 ► Air leak from the lung (pneumothorax) requiring 
drainage via needle thoracocentesis or intercostal 
catheter insertion.
 ► Death before discharge from hospital.
All incidences of these SAEs are reported to the lead 
Human Research Ethics Committee and to committees 
at the relevant site.
The DSMC may make a recommendation to the 
Steering Committee to temporarily or permanently stop 
the trial. Although no formal stopping rule will be used, 
such a decision may be based on:
 ► A difference in the primary outcome such that the 
committee considers the trial should no longer 
continue.
 ► An increase in the rate of SAEs in the nHF group.
 ► Equipment failure or unforeseen complications 
pertaining to the equipment or its manufacture.
 ► New information such as other trial results which 
make it ethically impossible to continue the trial.
The primary outcome review was completed in December 
2016, and on the basis of this, and on safety reviews 
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conducted to date, the DSMC has recommended that the 
trial continue without modification.
dissemination of results
The results of the trial will be published in a peer-re-
viewed journal and will be presented at national and 
international conferences.
current status and study duration
The trial began recruiting in April 2015, with additional 
sites joining subsequently. It is currently recruiting in eight 
centres, with one previous site ceasing recruitment due to a 
change in its level of care classification, meaning that it could 
no longer care for infants requiring prolonged non-invasive 
respiratory support. To the end of March 2017, over 500 
infants have been enrolled in the trial. It is expected that 
recruitment for the study will be completed in 2018.
dIScuSSIon
nHF therapy has been widely adopted in neonatal prac-
tice due to its desirable qualities such as ease of use, 
reduced nasal trauma and parental and nursing prefer-
ence.17–20 Recently, the HIPSTER trial demonstrated that 
in NICUs, rates of treatment failure with nHF are higher 
than with CPAP in preterm infants born ≥28 weeks’ 
GA, although with ‘rescue’ CPAP available there is no 
difference in rates of intubation.24 The HIPSTER results 
suggest that CPAP should be favoured over nHF if only 
one treatment is available; however, these findings cannot 
be directly applied to environments other than the NICU. 
The other recently published trial of primary nHF was 
also performed in a NICU and it included a high rate of 
surfactant administration by the INSURE technique, an 
intervention which is not currently practised routinely in 
Australian SCNs, and that has not been well-studied in 
the SCN setting or in the infant population relevant to 
SCNs (infants ≥31 weeks’ GA).28
There has traditionally been a lack of clinical research 
in newborn infants cared for in non-tertiary SCNs and 
only one previous RCT of respiratory support in this 
setting.6 Research in SCNs is important because care of 
infants in these units incorporates a number of factors 
distinct from tertiary NICUs. Non-tertiary SCNs do not 
care for large numbers of very preterm or very low birth 
weight infants and often need to treat term infants with 
respiratory distress. The resources and staffing available 
in non-tertiary SCNs are different from those in NICUs, 
and while capable of intubation and mechanical ventila-
tion as a stabilisation measure, SCNs are not equipped 
to provide this level of treatment for longer periods. The 
implications for failure of non-invasive support are there-
fore greater in SCNs: transfer of the infant to a NICU and 
separation from his or her parents. Furthermore, there 
are potentially important financial implications of treat-
ment failure: retrieval by specialist neonatal transport 
services, particularly when over long distances, as would 
apply in many areas of Australia, bears a significant cost. 
Transfers from SCNs also have an impact on staffing and 
resource allocation in receiving tertiary NICUs.
There has never been a randomised trial of nHF in 
non-tertiary SCNs; nHF may be an effective mode of 
support in this setting and, due to its ease of use, would be 
preferable to CPAP if shown to be non-inferior. However, 
it is equally important to determine if nHF is unsafe or 
significantly inferior to CPAP, so that clinicians may be 
guided to avoid nHF use in non-tertiary SCNs. If nHF use 
was associated with a reduction in nursing workload, it 
may prove to be more cost-effective than CPAP or may 
result in a greater capacity to manage infants requiring 
non-invasive support in SCNs. CPAP is associated with 
an increased risk of pneumothorax in comparison with 
oxygen treatment.6 A Cochrane Review noted nHF 
treatment to be associated with a small reduction in 
pneumothorax rate compared with CPAP.20 If a lower 
rate of this complication was seen in our trial with nHF, 
in conjunction with non-inferiority in treatment efficacy, 
nHF could be the preferred mode of treatment.
The HUNTER trial is a well-powered, carefully 
designed randomised clinical trial, which will determine 
whether nHF is an appropriate mode of early respiratory 
support for newborn infants in the non-tertiary setting. 
The non-inferiority design used in the HUNTER trial was 
until recently quite rare but has been used recently in 
similar trials by our group.24 31 The choice of non-inferi-
ority margin of 10% was made in view of the fact that the 
primary outcome was treatment failure and not a more 
critical outcome, such as death, and that infants who have 
treatment failure on nHF will be offered CPAP, which 
may ‘rescue’ them from intubation and/or transfer to a 
NICU, as seen in previous NICU trials of nHF.24 31 32
A potential limitation to this trial is that blinding of 
treatment allocation is not possible. We have attempted to 
minimise this by setting objective treatment failure criteria, 
which were agreed on by all participating centres. Some 
infants allocated to nHF will receive a brief period of CPAP 
before randomisation, which conceivably could affect inter-
pretation of the results. However, we have aimed to restrict 
the impact of this by excluding infants who have received 
two or more hours of CPAP from the trial, which we felt to 
be the shortest window in which seeking parental consent 
would be feasible. The HUNTER trial is a pragmatic trial, 
designed to assess whether nHF is non-inferior to CPAP 
in real-world practice. We have not mandated the need or 
timing of investigations such as chest X-rays or blood gas 
analysis nor have we protocolised the decision to treat 
infants with non-invasive support, which remains at clinician 
discretion. We acknowledge that some randomised infants 
may have recovered from respiratory distress without the 
use of non-invasive support or may have an unrecognised 
pneumothorax if randomised prior to a chest X-ray being 
performed.
The use of nHF in NICU practice is well-established 
and supported by evidence from multiple RCTs. However, 
nHF use is also being adopted in non-tertiary SCNs,9 13–15 
a setting in which there is little evidence of its efficacy 
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and safety. If this trial demonstrates that nHF is non-in-
ferior to CPAP as primary support for newborn infants in 
non-tertiary SCNs, then many units worldwide are likely 
to incorporate nHF into their routine practice. However, 
if nHF is inferior to CPAP, the results of this study will 
ensure that this treatment is not applied inappropriately, 
and infants in non-tertiary SCNs with respiratory distress 
will continue to receive evidence-based care. 
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